Abstract
Background/Aims: Autoimmune hepatitis shows a good response to immunosuppressive treatment, and the prognosis may be determined by the clinical course. The present study was conducted in order to analyze the factors contributing to the outcomes of patients with type 1 autoimmune hepatitis. Methods: Eighty-four consecutive patients with type 1 autoimmune hepatitis were followed up regularly for a median follow-up period of 70.5 months (16.2-163 months). We analyzed the prognostic factors using time-fixed and time-dependent Cox proportional hazard models. The end point was progression of the disease to decompensated liver cirrhosis. Results: Seventy-seven patients (92%) were treated with prednisolone during the follow-up period, and 11 patients (13%) developed decompensated liver cirrhosis. Using a time-dependent multivariate model, the starting dose of corticosteroid (dose of prednisolone 40 IU/L), all showed a significant association with progression of the disease. Conclusions: The prognosis of type 1 autoimmune hepatitis on adequate immunosuppressive treatment improves when the serum alanine aminotransferase level persists at ≤40 IU/L. Factors existing prior to medical treatment may not affect the prognosis.
| Original language | English |
|---|---|
| Pages (from-to) | 951-957 |
| Number of pages | 7 |
| Journal | Journal of Hepatology |
| Volume | 43 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2005 |
Fingerprint
Keywords
- Alanine aminotransferase
- Corticosteroid treatment
- Time-dependent Cox proportional hazard model
- Type 1 autoimmune hepatitis
ASJC Scopus subject areas
- Gastroenterology
Cite this
Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. / Miyake, Yasuhiro; Iwasaki, Yoshiaki; Terada, Ryo; Takagi, Shinjiro; Okamaoto, Ryoichi; Ikeda, Hiroshi; Sakai, Nobuyuki; Makino, Yasuhiro; Kobashi, Haruhiko; Takaguchi, Kouichi; Sakaguchi, Kohsaku; Shiratori, Yasushi.
In: Journal of Hepatology, Vol. 43, No. 6, 12.2005, p. 951-957.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis
AU - Miyake, Yasuhiro
AU - Iwasaki, Yoshiaki
AU - Terada, Ryo
AU - Takagi, Shinjiro
AU - Okamaoto, Ryoichi
AU - Ikeda, Hiroshi
AU - Sakai, Nobuyuki
AU - Makino, Yasuhiro
AU - Kobashi, Haruhiko
AU - Takaguchi, Kouichi
AU - Sakaguchi, Kohsaku
AU - Shiratori, Yasushi
PY - 2005/12
Y1 - 2005/12
N2 - Background/Aims: Autoimmune hepatitis shows a good response to immunosuppressive treatment, and the prognosis may be determined by the clinical course. The present study was conducted in order to analyze the factors contributing to the outcomes of patients with type 1 autoimmune hepatitis. Methods: Eighty-four consecutive patients with type 1 autoimmune hepatitis were followed up regularly for a median follow-up period of 70.5 months (16.2-163 months). We analyzed the prognostic factors using time-fixed and time-dependent Cox proportional hazard models. The end point was progression of the disease to decompensated liver cirrhosis. Results: Seventy-seven patients (92%) were treated with prednisolone during the follow-up period, and 11 patients (13%) developed decompensated liver cirrhosis. Using a time-dependent multivariate model, the starting dose of corticosteroid (dose of prednisolone 40 IU/L), all showed a significant association with progression of the disease. Conclusions: The prognosis of type 1 autoimmune hepatitis on adequate immunosuppressive treatment improves when the serum alanine aminotransferase level persists at ≤40 IU/L. Factors existing prior to medical treatment may not affect the prognosis.
AB - Background/Aims: Autoimmune hepatitis shows a good response to immunosuppressive treatment, and the prognosis may be determined by the clinical course. The present study was conducted in order to analyze the factors contributing to the outcomes of patients with type 1 autoimmune hepatitis. Methods: Eighty-four consecutive patients with type 1 autoimmune hepatitis were followed up regularly for a median follow-up period of 70.5 months (16.2-163 months). We analyzed the prognostic factors using time-fixed and time-dependent Cox proportional hazard models. The end point was progression of the disease to decompensated liver cirrhosis. Results: Seventy-seven patients (92%) were treated with prednisolone during the follow-up period, and 11 patients (13%) developed decompensated liver cirrhosis. Using a time-dependent multivariate model, the starting dose of corticosteroid (dose of prednisolone 40 IU/L), all showed a significant association with progression of the disease. Conclusions: The prognosis of type 1 autoimmune hepatitis on adequate immunosuppressive treatment improves when the serum alanine aminotransferase level persists at ≤40 IU/L. Factors existing prior to medical treatment may not affect the prognosis.
KW - Alanine aminotransferase
KW - Corticosteroid treatment
KW - Time-dependent Cox proportional hazard model
KW - Type 1 autoimmune hepatitis
UR - http://www.scopus.com/inward/record.url?scp=27744580616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744580616&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2005.06.006
DO - 10.1016/j.jhep.2005.06.006
M3 - Article
VL - 43
SP - 951
EP - 957
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 6
ER -